2024-11-15  5:35:47 PM Chg. -27.45 Volume Bid2024-11-15 Ask2024-11-15 Market Capitalization Dividend Y. P/E Ratio
437.15EUR -5.91% 675
Turnover: 301,973
-Bid Size: - -Ask Size: - 112.63 bill.EUR - -

Business description

Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative medicines so people with serious diseases can lead better lives. In addition to its clinical development programs focused on cystic fibrosis, Vertex has more than a dozen ongoing research programs aimed at other serious and life-threatening diseases. Founded in 1989 in Cambridge, Mass., Vertex today has research and development sites and commercial offices in the United States, Europe, Canada and Australia. For five years in a row, Science magazine has named Vertex one of its Top Employers in the life sciences.
 

Management board & Supervisory board

CEO
Reshma Kewalramani, M.D.
Management board
Charles F. Wagner, Jr., David Altshuler, Stuart A. Arbuckle, Jonathan Biller, Carmen Bozic, Amit K. Sachdev, Bastiano Sanna, Nia Tatsis, E. Morrey Atkinson, Ph.D.
Supervisory board
Dr. Jeffrey Leiden, Bruce I. Sachs, Diana McKenzie, Dr. Alan Garber, Dr. Sangeeta N. Bhatia, Lloyd Carney, Reshma Kewalramani, Terrence C. Kearney, Suketu (Suky) Upadhyay
 

Company data

Name: Vertex Pharmaceuticals Inc.
Address: 50 Northern Avenue,Boston, Massachusetts 02210, USA
Phone: +1-617-961-7163
Fax: -
E-mail: Investorinfo@VRTX.com
Internet: www.vrtx.com/
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12-31
Free Float: 82.70%
IPO date: 1991-07-24

Investor relations

Name: Susie Lisa
IR phone: +1-617-341-6108
IR Fax: -
IR e-mail: investorinfo@vrtx.com

Main Shareholders

Others
 
53.31%
Vanguard Group
 
8.63%
BlackRock Inc.
 
8.48%
Capital World Investors
 
8.45%
FMR LLC.
 
5.03%
State Street Corporation
 
4.68%
ALLIANCEBERNSTEIN L P
 
2.73%
PRICE T ROWE ASSOCIATES INC MD
 
2.28%
GEODE CAPITAL MANAGEMENT LLC
 
2.20%
Others
 
4.21%